drugset / Trial / NCT07601646

A Single-Arm, Dose Escalation of an Intraurethral Alprostadil Paste for Erectile Dysfunction

NCT07601646

Phase 2 Recruiting 83 enrolled Ryan Flannigan, MD
NaSingle-groupOpen-labelTreatment

Summary

This is a single arm dose escalation trial of a mucoadhesive intraurethral polymer suspension of alprostadil (ST-04) and will investigate the efficacy of 3 dose levels of ST-04 in adult males with a clinical diagnosis of Erectile Dysfunction (ED). This study aims to determine if ST-04, with or without sildenafil, will improve erectile function (EF) compared to baseline. Participants in this study will receive ST-04, a new formulation containing the vasodilator, alprostadil which is known to be an effective drug in treating erectile dysfunction. ST-04 will be dispersed along the urethra, forming a hydrogel which adheres to the lining of the urethra with the goal of penile tumescence and erection. Participants may receive up to 3 dose level escalations of ST-04 over a 12-week period, for a total of up to 11 administrations of ST-04. Dose escalation may also be done with and without sildenafil.

Timeline

Start
2026-05
Primary completion
2027-04
Completion
2027-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprostadil Unknown 500 ug Other
Subject Alprostadil Unknown 1000 ug Other
Subject Alprostadil Unknown 1500 ug Other

Indications